Back to news
Tech/Americas
Life Biosciences initiates first human clinical trial for cellular rejuvenation therapy
MULTIPLE REPORTS·Published ·Main source · Wired
Story essentials
Life Biosciences
Boston, USA
Original reports
Life Biosciences has treated the first participant in a gene therapy trial aimed at partially reprogramming aged cells.
The trial targets glaucoma and NAION, conditions causing optic nerve damage.
The approach uses three genes to restore youthful identity to cells, with safety monitored via a doxycycline-controlled switch.
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policyRelated book
Affiliate / Ad
Ageless: The New Science of Getting Older Without Getting Old
Author: Andrew Steele
This book provides a comprehensive overview of the biological mechanisms of aging and the cutting-edge interventions, including cellular reprogramming, that are currently being developed to extend human healthspan.
As an Amazon Associate, COMPAMIR earns from qualifying purchases.